Missions The major missions of the Medical Imaging Department are
To provide high quality diag- nostic and therapeutic services using radioactive elements.
To carry out translational and early clinical research, with a particular focus on new targeted treatments.
To deliver high quality pre- and postgraduate teaching in nuclear oncology.
To integrate imaging into the multidisciplinary oriented ap- proach to patient care.
THORACIC ONCOLOGY LABORATORY
FielD, technologies anD MethoDs
the laboratory focuses on both basic and translational research, including:
Study of precancerous lesions to identify new targets enabling the early detection of lung cancers by non-invasive means
Study of the biology of lung cancer, from its earliest stages to metastatic disease
Research aiming to identify biological and clinical prognostic factors for lung cancer
Research about predictive markers to evaluate the response of lung cancers to targeted therapies, such as tyrosine kinase inhibitors
Evaluation and study of the combination of innovative therapies with chemotherapy, such as histone deacetylase inhibitors in mesothelioma and small cell lung cancer
The Laboratory is also involved in numerous international collaborations with institutions and research groups such as the following:
Centre de Recherche Public-Santé (Luxembourg); Intergroupe Francophone de Cancérologie Thoracique (France); Centre Hospitalier Universitaire de Caen (France); Unité INSERM U774 de l’Institut Pasteur de Lille (France); University of Colorado (USA); International Association for Lung Cancer Study; and the European Lung Cancer Working Party.
Improv ng screening for thoracic cancers (lung cancer, mesothelioma and pulmonary metastases)
Studying the biology of thoracic cancers, including prognostic factors
Developing new treatments and molecular signatures predicting response to treatment
The Laboratory comprises 4 specialists in thoracic oncology, 1 research physician, 1 research nurse and 2 technicians.
Nathalie Leclercq Research Nurse
Prof Thierry Berghmans Medical Oncologist
Prof Jean-Paul Sculier Internist, Head of Laboratory
the Future Establishing methods for early and non-
invasive means of diagnosing thoracic cancers
Developing novel targeted treatments tailored to the needs of individual patients
recent eVolution Recent studies have shown that treatment with adjuvant chemotherapy can improve the survival of patients with completely resected stage II and III non-small cell lung cancer. The survival of patients with stage III unresectable non-small cell lung cancer is also improved when chemotherapy and radiotherapy are given concurrently rather than sequentially.